The stocks of MRNA have been issued with a rating of hold by around nineteen different analysts covering the firm. According to a report, three of the investment analysts have already provided the company with a rating of sell, while seven others have given the company a rating of hold. Close to eight others have issued the company with a rating of buy. Currently, the price target of the company over a period of a year has been $178.92.
The Stock Commentary Of MRNA
There have been quite a few research equities that have commented on the stocks of MRNA. Morgan Stanley has already reduced the price target of the company from $201 to $190 with a rating of equal weight in a 7th May research report. Zacks Investment Research has also reduced the rating of the company from buy to hold with a price target of $170 in a 20th April research report.
Brookline Capital Management has also increased the price target of the company from $180 to $205 with a rating of buy in a 26th February research report. SVB Leerink has decidedly issued a rating of sell on the company in an 18th April research report.
The stocks of MRNA traded on Thursday at $197.84. The market cap of the company is $79.44 billion, with the PE ratio set at 158.27, and a PEG ratio of around 0.73. The current ratio of the company is 1.39, with a 1.33 quick ratio, and a debt-to-equity ratio of around 0.04. The moving average price of the company over a period of 50 days is $174.81. The year low of the company is $54.21, with the year high of around $227.71.
MRNA previously announced the quarterly reports on the 6th of May. The EPS reported by the company during this quarter was $2.84, which was more than the consensus estimate of $2.04. The revenue generated by the company during this period was $1.94 billion, which was quite lower than the consensus estimate of $2.48 billion. The net margin for the company was 21.90%, with a 19.76% return on equity.